Editor-in-Chief - Global Journal of Immunology and Allergic Diseases

Dr. Liu began

Dr. Liu began his studies in 1983 at the Henan Medical University in Zhengzhou, China, where he graduated with a degree in Medicine (MD). He then started working as a residence in Department of Medicine, the Second Affiliated Hospital of Henan Medical University. He completed his academic studies with a PhD in mucosal immunopathology of inflammatory bowel disease (IBD) from the University of Leuven in Belgium. He then made his way to the United States and joined Beth Israel Deaconess Medical Center in Harvard Medical School and University of Connecticut Health Center as a Research Fellow. It was there that he investigated intestinal mucosal immune responses and inflammatory injury.

In 2005 Dr. Liu moved back to China and worked as a Professor of Medicine and Gastroenterologist in the Second Affiliated Hospital of Zhengzhou University, Zhenghou, China. He served as a physician scientist to take care of his IBD patients and focused on basic research in intestinal mucosal immunology. With extraordinary achievement in clinical and mucosal immunology study, he was then promoted to become the Chairman of the Department of Gastroenterology, Shanghai Tenth People’s Hospital of Tongji University in Shanghai, China.

While completing his PhD training, Dr. Liu became interested in intestinal mucosal immunology, with specific opportunities in IBD. He received several grants from “Crohn’s & Colitis Foundation of America, CCFA” and “National Nature Scientific Foundation of China”. He has found that profound proinflammatory cytokines (e.g., IL-15, IL-21, IL-23) as well as costimulatory molecules (eg., CD40, CD80) are present in inflamed intestinal mucosa of IBD patients. Targeted therapy directed against either CD40 ligand or IL-12 or TNF could effectively prevent experimental colitis in murine colitis models. Importantly, Dr. Liu observed that IL-21 and IL-23 strongly promotes IBD NK cell activation and cytolytic activities and induces mucosal CD4 T cell differentiation. All of data prove that abnormal immune response plays a critical role in the development of IBD. The importance of his research work will allow physicians and scientists to perform basic research in the field of IBD, but can develop clinical trials to test new therapies.

Dr. Liu serves as an “ad hoc reviewer” for J Immunol, Inflamm Bowel Dis, Clin Exp Immunol, Clin Immunol, J Leukocyte Biol. He has published more than 200 original papers in international and native journals, such as J Immunol, J Biol Chem, Inflamm Bowel Dis.

© 2017 Synchro Publisher
All rights reserved. SynchroPublisher.com
Back to Top